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Abstract 
Introduction:  
Human infection with multidrug resistant mycobacterium bovis (MDR-M.bovis) is very rare.  Recently, infection 
with this type of bacteria has been described. The WHO strategy to end TB by 2035, recall for more efforts in the 
diagnosis and treatment of mycobacterium bovis particularly in resource limited countries. The aim of this 
systematic review was to determine the prevalence of multidrug resistant tuberculosis M.bovis infects human.  
Methods: 
International database including Medline, EMBASE, and Web of Sciences, Scopus, and ScienceDirect were 
searched for related literature. Google Scholar searching engines as well as references list were explored. Studies 
met the inclusion criteria were included in the systematic review. Random effects model was used to estimate the 
pooled prevalence.  
Results: 
A total number of (4275) studies were retrieved and nine studies were included in the meta analysis. The overall 
estimated prevalence of the multidrug resistant Mycobacterium bovis was 0.04 (95% CI: 0.02, 0.06). Based one 
study quality, time and area of study, subgroup analysis were conducted to check for heterogeneity. The prevalence 
of MDR-M bovis in low quality studies was 0.04 (95% CI: 0.00, 0.06), and in high quality studies was 0.05 (95% 
CI: 0.02, 0.08).  
Conclusions: 
The finding of this study indicated that the prevalence of multidrug resistant M.bovis in human is low. However, 
more attention is needed in the diagnosis and treatment of M.bovis infection in Human. 
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Introduction 
Tuberculosis is main public health problem in the worldwide, despite the efforts that made to control the disease. 
According to the World Health Organization report 2016, the estimated new tuberculosis cases were 10.9 million 
with 1.4 million deaths [1]. Although the infection with Mycobacterium tuberculosis is the main cause of human 
tuberculosis, there are other species within mycobacterium complex can cause the disease such as M.bovis and M. 
Africanum [2]. M.bovis infects a large range of domesticated and wild animals and infection spread from these 
animals to humans [3]. Many studies provided evidence of the human-to-human transmission of M.bovis as well 
as transmission of the pathogen from patients to animals [4, 5]. M.bovis transmits from infected animals to humans 
through the consumption of unpasteurized milk and dairy products [6]. But, in recent year due to the currents 
pasteurization processes infection occur due to close contact through inhalation of droplets or handing of carcasses 
from infected animals. 
Human infection with mycobacterium bovis is very rare and mainly occurs among immune-compromised 
patients and as nosocomial in HIV patient [5]. Another evidence of human to human transmission of M.bovis has 
been  reported from study conducted in USA [7]. Moreover, M.bovis was accounted for 1.9% of all reported cases 
of tuberculosis in Spain between 2004 -2007 [8]. In a separate study conducted in Morocco among 200tuberculosis 
suspected patients reported 17.8 % infection with m.bovis [9]. In Ethiopia and Nigerian M.bovis infection in human 
has been reported and accounted for 17.0 % and 15.4 % of all tuberculosis cases respectively [10, 11]. Moreover, 
M.bovis has been isolated from sputum samples collected from tuberculosis suspected patients in Egypt and the 
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prevalence was  2.2% [12].  
Multi-drug resistance tuberculosis defines as resistance to at least rifampin and isoniazid. In 2015 there were 
480 000 new multi-drug resistance tuberculosis (MDR-TB) cases according to the World Health Organization 
report. MDR-TB has become a major health problem not only in developing countries, but Worldwide. MDR-TB 
cases have been reported   in many regions of the World [12]. Although MDR-TB is mainly developed from 
infection with mycobacterium tuberculosis, MDR-M.bovis outbreaks have been  reported [13, 14]. In Spain, 
M.bovis strains resistant to both rifampin and isoniazid were isolated from tuberculosis patients [8]. 
Several publications have reported the infection with multidrug resistance due to m.bovis. For instance, one 
study conducted in Buenos Aires, Argentina indicated that MDR-M.bovis has been reported  in 3% of patients 
infected with M.bovis[15]. Meanwhile, three samples of  MDR-tuberculosis were isolated from 89 human samples 
of M.bovisin study  conducted in Spain was      between 2004- 2007 [8]. Furthermore, study conducted in Argentina 
point out that MDR-M.bovis could be transmitted from human to human where M.bovis was isolated from 
household contact patients. Two sample of MDR –M.bovis (1%) were isolated from Mycobacterium tuberculosis 
complex samples collected from TB patientsin Spain [16]. In a separate study published in 2015 in Mexico,  
indicated that the rate of the MDR due to M.bovis infection was 38.5% [17]. These studies showed a significant 
variability in reporting  the MDR tuberculosis that caused by mycobacterium bovis. Thorough investigation is 
needed to reveal the importance of M.bovis infection in human Worldwide. The aim of this study is to follow 
systematic review to determine  the prevalence of MDR- M.bovis in humans . The aim of this systematic review 
and meta-analysis was to determine the overall prevalence of the multidrug resistance M.bovis in the world. 
 
Materials and Methods 
Searching strategy: 
Literature search was conducted independently by two authors (Adel + Mutasim)   using the Preferring Reporting 
Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [18]. Databases searched for literature 
review included Medline, EMBASE, and Web of Sciences, Scopus, and ScienceDirect. Google Scholar searching 
engine as well as references list was checked to strengthen the search for missed literatures. Keywords such as 
MDR-M.bovis, Mycobacterium Bovis, multi-drug resistance and resistant M.bovis were used to extract studies. 
We used the following strategy to search on Pubmed; #1Tuberculosis, Multidrug-Resistant [Mesh terms], #2Multi-
Drug Resistant Tuberculosis [tw], #3 Tuberculosis, MDR [tw], #4 MDR Tuberculosis [tw].#5 (#1 OR #2 OR #3 
OR #4).#6 Prevalence [Mesh terms], #7 Incidence [Mesh terms], #8 (#6 OR #7) , #9 Mycobacterium bovis [Mesh 
terms],  and #10 (#5 AND #8 AND #9). Related conference abstract books were searched for unpublished studies. 
 
Studies inclusion criteria: 
Studies that reported Mycobacterium bovis as a causative agent for multidrug resistance tuberculosis in human 
was retrieved. Studies were searched regardless of their place, publication year and language. Multidrug resistance 
Mycobacterium bovis studies that reported  resist to both Isoniazid and Rifampicin were included in the analysis. 
The outcome of the interest was the prevalence of multidrug resistance Mycobacterium bovis. Conventional drug 
susceptibility testing as well as molecular techniques to detect the multidrug resistance were considered as the 
main test to select studies. Two authors were independently screen the title and abstract of the retrieved studies. If 
anystudy  met the inclusion criteria they reviewed the full contents. The second stage was reviewing the contents 
of the studies that met the criteria in the first stages. If  two authors agreed on study, it would be reviewed in detail. 
In the case of any disagreement in the selection of studies, it resolved by discussion and judgment by a third author.   
 
Data collection and validity assessment: 
The New Castle-Ottawa Scale (NOS) for assessing the nonrandomized studies in meta-analysis was followed to 
assess the risk of bias for the extracted studies [19]. Two authors (A and M) were responsible  to conduct the 
quality assessment. Study selection items included (a) criteria to have representative participants; (b) how to reach 
justified and satisfactory sample size (c) how demographic characteristics of study participants were established; 
(d) description of the location, setting, date, and related items; (e) methods of the assessment of the outcomes; and 
(f) Analysis the report of the  interested outcomes. Studies were categorized as likely if it satisfied all the criteria, 
intermediate if it did not meet two criteria, and unlikely if it did not meet more than two criteria. The extracted 
data included the author, location, year of publication, the sample size, and the diagnostic test.  Interested outcome 
of this study  was the number of the multidrug resistant Mycobacterium bovis..  
 
Heterogeneity: 
The heterogeneity among   studies was assessed by computing the value of the chi-square (Q) at 10% significance 
level. Heterogeneity across the results of studies was quantified by I2, while tau-square (Tue2) was used to assess 
the between study heterogeneity [20].  
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Statistical analysis: 
The primary outcome measure was the MDR-M.bovis prevalence. The standard error of the prevalence was 
calculated using binomial probability distribution. Overall and subgroup pooled prevalence was estimated using a 
random effects model with the inverse variance method. Stata 11 (Stata Corp., College Station, TX, USA) was 
used for the data analysis. Graphical display of results of each individual study on common scale ( Forest plot) 
was used to visualize effects of different studies.  
 
Results: 
Multidrug resistant Mycobacterium bovis was reported in Europe in Spain, France, Scotland, Netherland, and Italy 
[21-25]. In North America, the resistant bacteria of M.bovis had been isolated from patients in USA , Canada and 
Mexico [26], [27], [28]. Multidrug resistant Mycobacterium bovis has been reported from Argentina [29] in South 
America, from Burkina Faso in Africa [30], and Pakistan in Asia [31].  
A total number of (4275) studies with 16091 participants were retrieved up to December 2017 through 
searching international database. From retrieved studies, (4112) studies were excluded because they did not relate 
to the objective of the systematic review. In addition, (128) studies were excluded because of duplication or full 
text was not accessible. Therefore, 35 full text studies were eligible for in-depth analysis (Figure 1). Then, (20) 
studies were excluded because they did not meet the eligibility criteria to be included in the Meta analysis. Another 
six studies were excluded due to small sample size. The remaining studies (9)  were met the inclusion criteria for 
the Meta analysis (Table 1), [32], [33], [34], [35], [36], [37], [38] ], [39], [ 40]. 
 
Heterogeneity: 
High heterogeneity was observed among studies included in the Meta-analysis. Based on the results of the 
heterogeneity tests, the results of included studies were significantly heterogeneous, I2=94.1% (P=0.001. The I2 
among high quality studies was 94.68 %, whereas among low quality heterogeneity was 89.85%. Subgroup 
analysis based on the quality of studies reduced the heterogeneity among low quality studies.   
 
The prevalence of MDR-M.bovis: 
The pooled estimated prevalence of the multidrug resistant Mycobacterium bovis was 0.04 (95% CI: 0.02, 0.06) 
(Figure 2).  The prevalence of high quality studies was 0.05 (95% CI: 0.02, 0.08), and low quality studies was 0.04 
(95% CI: 0.02, 0.06). The prevalence of MDR-M bovis in Spain was 0.04 (95% CI: 0.02, 0.06). 
 
Figure 1: Stages for eligibility criteria and study selection flow chart 
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Table 1: Description of studies included in Meta-analysis  
 
Study 
 
Year 
 
Country 
 
Patients 
Sample 
size 
Mean 
age 
DST* + Genotyping HIV 
status 
 
Antonio 
Guerrero             
 
1997 
 
Spain 
 
19 
 
434 
 
31 
RFLP** + 
Genotyping  
HIV 
Antonio Rivero               2000 Spain 31 435 35 DST HIV 
J. Cobo                                2001 Spain 19 1353  RFLP HIV 
ANNETTE T                  2002 USA 2 143  RFLP + Genotyping.  
Carlos Y                         2004 Spain 24 241  DST + RFLP  
J. Esteban                       2005 Spain 7 1366 50 DST   
M. Tato                          2006 Spain 2 55  DST + Genotyping.  
E. Cordova                       2012 Argentina 1 97  PCR + MIRU-
VNTR***  
HIV 
Miriam 
Bobadilla             
2015 Mexico 89 1165  DST + MIRU-VNTR  
* Drug susceptibility test 
** Restriction fragment length polymorphism 
*** Variable-number tandem repeats of mycobacterial interspersed repetitive units 
 
 
Figure 2: Forest plot of the prevalence of the Multidrug resistant M.bovis 
 
Discussion 
Our study focused on the review of studies reported Mycobacterium bovis resistant to both rifampicin and 
Overall  (I^2 = 94.13%, p = 0.00)
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Isoniazid. According to our knowledge, this is a first systematic review and Meta-analysis summarizes articles 
report the multidrug resistant M.bovis. The Meta analysis findings indicated that the prevalence of multidrug 
resistant Mycobacterium bovis among human was 1%. The prevalence of studies conducted before 2010 was 2%, 
where the prevalence of studies conducted after that was 0.8%. According to theWHO, the global burden of 
multidrug resistant tuberculosis is 4.1% [41].  Most of retrieved studies concern with MDR-M bovis were 
conducted either in Europe or in United State of America (North and South) and only one study was reported from 
Burkina Faso in Africa. The majority of studies were retrieved from Europe, particularly Spain. It was obvious 
that developed countries  had capacity to investigate different types of mycobacteria causing multidrug resistant. 
This indicates that the prevalence of MDR Mycobacterium bovis has   a considerable  decreased. 
In spite of the development in molecular technique to diagnose all forms of tuberculosis, this was not reflected 
in developing countries. Attention should be paid to tuberculosis laboratories in developing countries because they 
have high burden of tuberculosis infection. It is  important to consider the occurrence of MDR M.bovis because 
many studies provided evidence that this pathogen has been isolated from animals. A recent study published in 
2017 reported that Mycobacterium bovis resistant to both rifampicin and isoniazid in a study conducted in Brazil 
[42]. 
It is worth mentioning that a considerable number of  laboratories in developing countries do not have the 
capacity to do mycobacterium culture and depend mainly on microscopic examination. In addition, laboratories 
that have culture for Mycobacterium pathogen, they don’t considere M.bovis in their routine work for a reason that  
this bacterium cannot grow in Media with Glycerol 43]. Also, M.bovis is naturally resisted to pyrazinamide so if 
the bacteria did not consider in the diagnosis of tuberculosis patient, this may lead to resistant phenomenon due to 
improper treatment. The WHO Report indicated that new TB case confirmed by bacteriology to test the drug 
susceptibility was very low ( 12% out of  2.7 million new cases) [44]. Tuberculosis laboratory that has the capacity 
to do bacterial culture should  add pyruvate inculture media. Many studies correlate the occurrence of multidrug 
resistant mycobacterium bovis in animals and human in Mexico and USA 45]. 
. According to the finding of this systematic review and meta-analysis, Bovine tuberculosis  is decreasing in 
Europe and North America where the last report was from Spain in 2009. It was obvious that the prevalence of 
human Mycobacterium bovis decreases after the implementing of prevention programme in Europe and North 
America[46]. On the other hand,  recent report  of multidrug resistant Mycobacterium bovis was from Burkina 
Faso in 2017. This is the only study reported report the occurrence of this diseases in  African continent [30]. 
Although bovine tuberculosis is prevalent in  African countries, measures to control this disease such as 
pasteurization and test-slaughter strategy are not applied 47]. Other factors might contribute in the risk to get the 
disease is the human behavior where people have close contact with animals particularly in rural areas. Also, high 
prevalence of  HIV increases the risk of  getting the disease [48]. So, this leads to that human more susceptible to 
infect with bovine tuberculosis. In Africa, 90 countries have reported the occurrence of Mycobacterium bovis 
among cattle population [49].  More efforts are required to reduce the burden of disease in Human and animals.This 
could be achieverd by setup a test slaughter strategy putting in mou mind  a suitable compensation policy in Africa. 
Polices, diseases surveillance system and clinical diagnose have to take M. bovis in to consideration. 
. Study conducted in Netherland reported M.bovis which was resisted  multiple second line drugs. This means 
that M.bovis not only resist to multiple first line tuberculosis drugs, but also resist to multiple second line drugs 
and might lead to Extensively drug resistant mycobacterium (XDR)  [50]. WHO end strategy to end TB by 2035, 
recall for more efforts in the diagnosis and treatment of Mycobacterium bovis particularly in resource limited 
countries. The strategy of  early diagnosis of tuberculosis and drug susceptibility testing should be considered to  
identify multidrug resistant mycobacterium bovis [51]. WHO, FAO, and World Organization for Animal Health 
together published the Roadmap of zoonotic tuberculosis in 2017 in order to highlight the need in defining different  
groups at risk to get the disease. In addition, funding bodies have  to address the detection and treatment of M. 
bovis activities by allocating funding to these activities [52]. 
This study has many limitations which include that the number  studies selected for  the Meta analysis was 
low. In addition, some studies have small sample size which might increase the risk of selection bias. The searching 
process included only articles that published in English. In addition, the systematic review and meta-analysis was 
based on published studies available online. 
 
Conclusion 
The systematic review provided evidence that multidrug resistant mycobacterium bovis infect human. According 
to the meta-analysis, the prevalence of this bacterium is low and more research is needed to figure out the exact 
burden of MDR-M. bovis particularly in low and middle income countries. Although this study was to estimate 
the pooled prevalence of multidrug resistant mycobacterium bovis using systematic review and Meta Analysis, it 
did not reflect the accurate prevalence because of the heterogeneity in the included studies.  
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